Late last year 2018, launch Biogen a new cohort study.
SPINRAZA in Adult Spinal Muscular Atrophy type 2 and 3 in age 18-70 , which is currently recruiting participants in the US and is targeting additional results.
The study will evaluate the safety, tolerability and effectiveness of SPINRAZA in adults with SMA.
In Germany adults are treated with Spinraza aswell and With positive results.
Spinraza in Adult Spinal Muscular Atrophy (SAS)
#study #adults #treatment #Spinraza